Cargando…
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts
Phosphoinositide 3-kinase α (PIK3CA) is one of the most mutated genes across cancers, especially breast, gynecologic, and head and neck squamous cell carcinoma tumors. Mutations occur throughout the gene, but hotspot mutations in the helical and kinase domains predominate. The therapeutic benefit of...
Autores principales: | Buckbinder, Leonard, St. Jean, David J., Tieu, Trang, Ladd, Brendon, Hilbert, Brendan, Wang, Weixue, Alltucker, Jacob T., Manimala, Samantha, Kryukov, Gregory V., Brooijmans, Natasja, Dowdell, Gregory, Jonsson, Philip, Huff, Michael, Guzman-Perez, Angel, Jackson, Erica L., Goncalves, Marcus D., Stuart, Darrin D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618743/ https://www.ncbi.nlm.nih.gov/pubmed/37623743 http://dx.doi.org/10.1158/2159-8290.CD-23-0396 |
Ejemplares similares
-
Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer
por: Hany, Dina, et al.
Publicado: (2023) -
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
por: Song, Kyung W., et al.
Publicado: (2022) -
Piano quartets K. 478 & K. 493
por: Mozart, Wolfgang Amadeus, 1756-1791
Publicado: (1998) -
Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers
por: Fernandes, Maria Sofia, et al.
Publicado: (2016) -
PI3Kα Inhibitors That Inhibit Metastasis
por: Schmidt-Kittler, Oleg, et al.
Publicado: (2010)